Pacritinib combined with sirolimus and low-dose tacrolimus for GVHD prevention after allogeneic hematopoietic cell transplantation: Preclinical and Phase I trial results

PURPOSE: In this first-in-human, phase I, graft-versus-host disease (GVHD) prevention trial (NCT02891603) we combine pacritinib (PAC), a JAK2 inhibitor, with sirolimus to concurrently reduce T-cell costimulation via mTOR and IL-6 activity. We evaluate the safety of pacritinib when administered with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Pidala, Joseph, Walton, Kelly, Elmariah, Hany, Kim, Jongphil, Mishra, Asmita, Bejanyan, Nelli, Nishihori, Taiga, Khimani, Farhad, Perez, Lia, Faramand, Rawan G., Davila, Marco L., Nieder, Michael L., Sagatys, Elizabeth M., Holtan, Shernan G., Lawrence, Nicholas J., Lawrence, Harshani R., Blazar, Bruce R., Anasetti, Claudio, Sebti, Said M., Betts, Brian C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8127396/
https://ncbi.nlm.nih.gov/pubmed/33753457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4725
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados